Filing Flows › Cytek Biosciences (CTKB) › R&D spending
Cytek Biosciences (CTKB) R&D spending by quarter
Cytek Biosciences' R&D spending was $9.4M in Q3 2026 (third quarter 2026), -4% from Q2 2026. Over the last 7 quarters it ranged from $8.8M (Q2 2025) to $9.7M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $9.4M | -4% | +4% |
| Q2 2026 | $9.7M | +1% | +10% |
| Q1 2026 | $9.6M | +7% | -1% |
| Q4 2025 | $9.0M | +0.1% | — |
| Q3 2025 | $9.0M | +1% | — |
| Q2 2025 | $8.8M | -9% | — |
| Q1 2025 | $9.7M | — | — |
Q3 2026 at a glance
Cytek Biosciences, Q3 2026: revenue $53.2M (+2% year over year), operating margin -15.8%, net loss $6.1M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Cytek Biosciences' R&D spending?
Cytek Biosciences' R&D spending was $9.4M in Q3 2026 (third quarter 2026), -4% from Q2 2026.
How has Cytek Biosciences' R&D spending changed?
Over the last 7 quarters it ranged from $8.8M (Q2 2025) to $9.7M (Q2 2026).